Yang Z B, Tsuchiya Y, Arika T, Hosokawa M
Central Research Laboratories, Kaken Pharmaceutical Co. Ltd. Kyoto.
Jpn J Cancer Res. 1993 May;84(5):538-43. doi: 10.1111/j.1349-7006.1993.tb00173.x.
The inhibitory effects of a biological response modifier (BRM), sizofiran, on sister chromatid exchanges (SCEs) in the bone marrow cells of mice treated with various anticancer agents or irradiation were investigated. Sizofiran (10 mg/kg i.m.) inhibited SCEs induced by mitomycin C (2 mg/kg i.v.), adriamycin (20 mg/kg i.v.) and cyclophosphamide (20 mg/kg i.v.) by about 20%, respectively. Analysis of the SCEs in vivo after irradiation plus sizofiran indicated that SCE levels were significantly lower than those observed in mice exposed to irradiation without sizofiran. Moreover, the effects of sizofiran were dependent on the timing of administration. Our results indicated that sizofiran should be administered simultaneously or soon after irradiation in order to minimize damage. Sizofiran also markedly restored the bone marrow cell mitosis which had been suppressed by anticancer agents, and this action was closely correlated with the prevention of increase in SCEs. These results indicate that in addition to immunopotentiating activity, sizofiran may play a role in preventing chromosomal damage induced by cancer chemotherapy and radiotherapy.
研究了生物反应调节剂（BRM）西佐喃对用各种抗癌药物或辐射处理的小鼠骨髓细胞中姐妹染色单体交换（SCE）的抑制作用。西佐喃（10毫克/千克，肌肉注射）分别使丝裂霉素C（2毫克/千克，静脉注射）、阿霉素（20毫克/千克，静脉注射）和环磷酰胺（20毫克/千克，静脉注射）诱导的SCE抑制约20%。对辐射加西佐喃后的体内SCE分析表明，SCE水平显著低于未使用西佐喃接受辐射的小鼠。此外，西佐喃的作用取决于给药时间。我们的结果表明，为了使损伤最小化，西佐喃应在辐射时或辐射后不久同时给药。西佐喃还显著恢复了被抗癌药物抑制的骨髓细胞有丝分裂，并且这种作用与防止SCE增加密切相关。这些结果表明，除免疫增强活性外，西佐喃可能在预防癌症化疗和放疗诱导的染色体损伤中发挥作用。
